Nephros Statistics
Total Valuation
Nephros has a market cap or net worth of $57.77 million. The enterprise value is $55.53 million.
Important Dates
The next estimated earnings date is Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nephros has 10.60 million shares outstanding. The number of shares has increased by 1.95% in one year.
| Current Share Class | 10.60M |
| Shares Outstanding | 10.60M |
| Shares Change (YoY) | +1.95% |
| Shares Change (QoQ) | +1.86% |
| Owned by Insiders (%) | 12.80% |
| Owned by Institutions (%) | 45.88% |
| Float | 9.24M |
Valuation Ratios
The trailing PE ratio is 45.73.
| PE Ratio | 45.73 |
| Forward PE | n/a |
| PS Ratio | 3.64 |
| Forward PS | 3.46 |
| PB Ratio | 6.34 |
| P/TBV Ratio | 7.14 |
| P/FCF Ratio | 29.73 |
| P/OCF Ratio | 29.73 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 37.57, with an EV/FCF ratio of 27.81.
| EV / Earnings | 41.85 |
| EV / Sales | 3.33 |
| EV / EBITDA | 37.57 |
| EV / EBIT | 41.53 |
| EV / FCF | 27.81 |
Financial Position
The company has a current ratio of 5.41, with a Debt / Equity ratio of 0.13.
| Current Ratio | 5.41 |
| Quick Ratio | 4.01 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.62 |
| Debt / FCF | 0.62 |
| Interest Coverage | 1,337.00 |
Financial Efficiency
Return on equity (ROE) is 15.14% and return on invested capital (ROIC) is 8.21%.
| Return on Equity (ROE) | 15.14% |
| Return on Assets (ROA) | 7.16% |
| Return on Invested Capital (ROIC) | 8.21% |
| Return on Capital Employed (ROCE) | 12.77% |
| Revenue Per Employee | $538,194 |
| Profits Per Employee | $42,806 |
| Employee Count | 31 |
| Asset Turnover | 1.43 |
| Inventory Turnover | 2.43 |
Taxes
In the past 12 months, Nephros has paid $24,000 in taxes.
| Income Tax | 24,000 |
| Effective Tax Rate | 1.78% |
Stock Price Statistics
The stock price has increased by +290.68% in the last 52 weeks. The beta is 1.33, so Nephros's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | +290.68% |
| 50-Day Moving Average | 4.62 |
| 200-Day Moving Average | 3.04 |
| Relative Strength Index (RSI) | 57.53 |
| Average Volume (20 Days) | 85,327 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nephros had revenue of $16.68 million and earned $1.33 million in profits. Earnings per share was $0.12.
| Revenue | 16.68M |
| Gross Profit | 10.57M |
| Operating Income | 1.34M |
| Pretax Income | 1.35M |
| Net Income | 1.33M |
| EBITDA | 1.48M |
| EBIT | 1.34M |
| Earnings Per Share (EPS) | $0.12 |
Full Income StatementBalance Sheet
The company has $5.07 million in cash and $1.24 million in debt, giving a net cash position of $3.83 million or $0.36 per share.
| Cash & Cash Equivalents | 5.07M |
| Total Debt | 1.24M |
| Net Cash | 3.83M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 9.60M |
| Book Value Per Share | 0.91 |
| Working Capital | 7.81M |
Full Balance SheetCash Flow
| Operating Cash Flow | 2.00M |
| Capital Expenditures | n/a |
| Free Cash Flow | 2.00M |
| FCF Per Share | $0.19 |
Full Cash Flow StatementMargins
Gross margin is 63.37%, with operating and profit margins of 8.01% and 7.95%.
| Gross Margin | 63.37% |
| Operating Margin | 8.01% |
| Pretax Margin | 8.10% |
| Profit Margin | 7.95% |
| EBITDA Margin | 8.86% |
| EBIT Margin | 8.01% |
| FCF Margin | 11.97% |
Dividends & Yields
Nephros does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.95% |
| Shareholder Yield | -1.95% |
| Earnings Yield | 2.24% |
| FCF Yield | 3.36% |
Analyst Forecast
The average price target for Nephros is $5.50, which is 0.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.50 |
| Price Target Difference | 0.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 10, 2019. It was a reverse split with a ratio of 1:9.
| Last Split Date | Jul 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
Nephros has an Altman Z-Score of -9.3 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.3 |
| Piotroski F-Score | 7 |
